Skip to content

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GOUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF CEFTAZIDIME AVIBACTAM (CAZ104) PLUS METRONIDAZOLE VERSUS MEROPENEM IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (cIAIs)IN HOSPITALIZED ADULTS.

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GOUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF CEFTAZIDIME AVIBACTAM (CAZ104) PLUS METRONIDAZOLE VERSUS MEROPENEM IN THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (cIAIs)IN HOSPITALIZED ADULTS.

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-007-12
Enrollment
120
Registered
2012-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

THE MINIMUM DURATION OF TREATMENT WITH IV STUDY THERAPY IS 5 FULL DAYS (15 DOSES) FOR PATIENTS WITH NORMAL RENAL FUNCTION OR MILD RENAL IMPAIRMENT AND THE MAXIMUM DURATION OF TRETAMENT WITH IV STUDY T
LEVELS: </=10 OR TO </=30) (SEE APPENDIX F) AND BY REGION (NORTH AMERICA AND WESTERN EUROPE, EASTERN EUROPE, AND THE REST OF THE WORLD). ADDITIONALY, ALTHOUGH NOT INCLUDED AS A STRATIFICATION FACTOR,

Sponsors

AstraZeneca AB,
Lead Sponsor

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: FOR INCLUSION IN THE STUDY PATIENTS SHOULD FULFILL THE FOLLOWING CRITERIA: 1. PATIENTS MUST PROVIDE A SIGNED WRITTEN INFORMED CONSENT PRIOR TO ANY STUDY-SPECIFIC PROCEDURES. HOWEVER, IF A PATIENT IS UNABLE, THE PATIENT´S LEGALLY ACCEPTABLE REPRESENTATIVE MAY PROVIDE WRITTEN CONSENT, AS APPROVED BY THE INSTITUCIONAL-SPECIFIC GUIDELINES. THOSE PATIENTS WHO ARE UNCONSCIOUS OR CONSIDERED BY THE INVESTIGATOR TO BE CLINICALLY UNABLE TO CONSENT AT SCREENING AND WHO ARE ENTERED INTO THE STUDY BY THE CONSENT OF LEGALLY ACCEPTABLE REPRESENTATIVE, SHOULD PROVIDE THEIR OWN WRITTEN INFORMED CONSENT FOR CONTINUING TO PARTICIPATE IN THE STUDY AS SOON S POSSIBLE ON RECOVERY, AS APPLICABLE IN ACCORDANCE WITH LOCAL REGULATIONS. 2. PATIENT MUST BE 18 TO 90 YEARS OF AGE INCLUSIVE. 3. WOMEN ARE AUTHORIZED TO PARTICIPATE IF THEY MEET THE FOLLOWING CRITERIA: (a) SURGICAL STERILIZATION OR (b) COMPLETED MENOPAUSE, AS DEFINED BY CRITERIA IN FOOTNOTE (1) (IF CRITERIA NOT MET, SHOULD BE REGARDED AS HAVING CHILDBEARING POTENTIAL). OR (c) FEMALE PATIENT CAPABLE OF HAVING CHILDREN AND AGREES NOT TO ATTEMPT PREGNANCY WHILE RECEIVING IV STUDY THERAPY AND FOR A PAERIOD OF 1 WEEK AFTER. ACCEPTABLE METHODS OF CONTRACEPTION FOR THIS STUDY ARE: . PRIOR TO AND DURING THE STUDY, USE OF AN INTRAUTERINE DEVICE, REGULAR DEPO-PROGESTERONE INJECTIONS, OR SEXUAL INTERCOURSE WHIT ONLY VASECTOMIZED PARTNERS. . COMPLETE SEXUAL ABSTINENCE FOR THE RECOMMENDED PERIOD. 4 EITHER: INTRAOPRATIVE/POSTO

Exclusion criteria

Exclusion criteria: PATIENTS SHOULD NOT ENTER THE STUDY IF ANY OF THE FOLLOWING EXCLUSION CRITERIA ARE FULFILLED: 1. PATIENT DIAGNOSED WITH TRAUMATIC BOWEL PERFORATION UNDERGOING SURGERY WITHIN 12 HOURS; PERFORATION OF GASTRODUODENAL ULCERS UNDERGOING SURGERY WITHIN 24 HOURS. OTHER INTRA-ABDOMINAL PROCESSES IN WHICH THE PRIMARY ETIOLOGY IS NOT LIKELY TO BE INFECTIOUS. 2. PATIENT HAS ABDOMINAL WALL ABSCESS OR BOWEL OBSTRUCTION WITHOUT PERFORATION OR ISCHEMIC BOWEL WITHOUT PERFOARTION. 3. PATIENT HAS SIMPLE CHOLECYSTITIS, OR GANGRENOUS CHOLECYSTITIS WITHOUT RUPTURE, OR SIMPLE APPENDICITIS, OR ACUTE SUPPURATIVE CHOLANGITIS, OR INFECTED NECROTIZING PANCREATITIS OR PANCREATIC ABSCESS. 4. PATIENT´S SURGERY WILL INCLUDE STAGED ABDOMINAL REPAIR, OR OPEN ABDOMEN TECHNIQUE, OR MARSUPIALIZATION. 5. PATIENT´S IS KNOWN AT STUDY ENTRY TO HAVE A cIAI CAUSED BY PATHOGENS RESISTANT TO THE STUDY ANTIMICROBIAL AGENTS. 6. PATIENT NEEDS EFFECTIVE CONCOMITANT SYSTEMIC ANTIBACTERIALS (ORAL, IV, OR INTRAMUSCULAR) OR ANTIFUNGALS IN ADDITION TO HOSE DESIGNATED IN THE 2 STDY GROUPS, EXCEPT VANCOMYCIN, LINEZOLID, OR DAPTOMYCIN IF STARTED FOR KNOWN OR SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREAUS (MRSA) OR ENTEROCOCCUS SPECIES AS PER PROTOCOL SECTION 5.6. 7. PATIENT HAS EVIDENCE OF SEPSIS WITH SHOCK NOT RESPONDING TO IV FLUID CHALLENGE OR ANTICIPATED TO REQUIRE THE AMINISTRATION OF VASOPRESSORS FOR > 12 HOURS. 8. PATIENT HAS PERINEPHRIC INFECTIONS. 9. PATIENT HAS INDEWELLING PERITONEAL DIALYSIS CAT

Countries

Argentina, Belgium, Brazil, Bulgaria, Czech Republic, Hungary, India, Israel, Mexico, Peru, Portugal, Romania, Russian Federation, South Africa, Spain, Taiwan, Thailand, Ukraine, United States

Contacts

Public ContactLuis Miguel Melendez

PPD Peru S.A.C.

Luis. Melendez@ppdi.com613-4126

Outcome results

None listed

Source: REPEC (via WHO ICTRP)